Filing Flows › Amphastar Pharmaceuticals (AMPH) › Capital expenditures
Amphastar Pharmaceuticals (AMPH) capital expenditures by quarter
Amphastar Pharmaceuticals' capital expenditures were $9.9M in Q3 2026 (third quarter 2026), +16% from Q2 2026. Over the last 7 quarters it ranged from $5.3M (Q3 2025) to $10.7M (Q1 2025).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $9.9M | +16% | +86% |
| Q2 2026 | $8.6M | -10% | -19% |
| Q1 2026 | $9.5M | +15% | -11% |
| Q4 2025 | $8.3M | +55% | — |
| Q3 2025 | $5.3M | -49% | — |
| Q2 2025 | $10.6M | -1% | — |
| Q1 2025 | $10.7M | — | — |
Q3 2026 at a glance
Amphastar Pharmaceuticals, Q3 2026: revenue $208M (+8% year over year), operating margin 24.5%, net earnings $37.8M, operating cash flow $43.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is Amphastar Pharmaceuticals' capital expenditures?
Amphastar Pharmaceuticals' capital expenditures were $9.9M in Q3 2026 (third quarter 2026), +16% from Q2 2026.
How has Amphastar Pharmaceuticals' capital expenditures changed?
Over the last 7 quarters it ranged from $5.3M (Q3 2025) to $10.7M (Q1 2025).
Q3 2026 results → · How Amphastar Pharmaceuticals makes money →